In contrast, all mIgG2a anti-TIGIT mAbs with intact FcγR binding (WT-TGT, SEA-TGT, and DLE-TGT) showed significant tumor growth delay in many of the disparate syngeneic models assessed. This evidence concerns the gene FCGR2A and neoplasm.